Complicated Skin and Skin Structure Infections (cSSSI’s): A Comprehensive Review

K V Ramana^1, , Venkata BharatKumar Pinnelli², Bhanu Prakash³, Wilma Delphine Silvia CR⁴, Sabitha Kandi⁵, CH V Sharada⁶, Anand Kalaskar¹, Sanjeev D Rao¹, Ratna Mani⁷ and Ratna Rao⁷

¹Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, India

²Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India

³Department of Dermatology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India

⁴Department of Biochemistry, Akash Institute of Medical Sciences & Research Center, Bangalore, India

⁵Department of Biochemistry, Chalmeda Anandarao Institute of Medical Sciences, Karimnagar, India

⁶Department of Microbiology, Prime Hospitals, Hyderabad, India

⁷Department of Microbiology, Apollo Hospitals, Jubilee Hills, Hyderabad, India

Cite this paper:
K V Ramana, Venkata BharatKumar Pinnelli, Bhanu Prakash, Wilma Delphine Silvia CR, Sabitha Kandi, CH V Sharada, Anand Kalaskar, Sanjeev D Rao, Ratna Mani and Ratna Rao. Complicated Skin and Skin Structure Infections (cSSSI’s): A Comprehensive Review. American Journal of Medical and Biological Research. 2013; 1(4):159-164. doi: 10.12691/ajmbr-1-4-9

Abstract

Complicated skin and skin structure infections (cSSSI’s) are among the most common microbial infections occurring both in the community and the hospitals. Aetiology of cSSSI’s is complex and includes various microorganisms (bacteria, fungi, parasites and viruses). cSSSI’s in general are poly microbial in nature including both anaerobic and aerobic bacterial species. Primary cSSSI’s resulting from single bacterial species and secondary bacterial infections in patients suffering from skin conditions due to autoimmune conditions (eczema) or other microbial causes (viruses, fungi and parasites) have been reported in the literature. Occurrence of multi-drug resistant bacteria, underlying co-morbidities contribute to the complications in the management of cSSSI’s. Formulating effective guidelines for clinical, laboratory diagnosis, treatment and management of patients suffering from cSSSI’s would certainly be beneficial in the reduction of morbidity and mortality.

Keywords:
complicated skin and skin structure infections (cSSSI’s) aetiology of cSSSI’s multi-drug resistance

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Rhody, C. Bacterial infections of the skin. Primary Care 2000; 27: 459-73.
[2]	Zilberberg MD, Shorr AF, Micek ST, et al. Hospitalizations with healthcare-associated complicated skin and skin structure infections: impact of inappropriate empiric therapy on outcomes. J Hosp Med 2010; 5:535-540.
[3]	Mathew S Dryden. Complicated skin and soft-tissue infection. J Antimicrob Chemother 2010; 65 Suppl S3: iii 35-44.
[4]	Mark J. DiNubile and Benjamin A. Lipsky. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004; 53 Suppl S2: ii37-ii 50.
[5]	P Kujath and C Kujath. Complicated skin, skin structure and soft-tissue infections -Are we threatened with multi-resistant pathogens? Eur J Med Res 2010; 15: 544-553.
[6]	Sabitha Rajan. Skin and soft-tissue infections: classifying and treating a spectrum. Claveland Clinic Journal of Medicine 2012; 79 (1): 57-66.
[7]	James I. Merlino and Mark A Malangoni. Complicated skin and soft-tissue infections: Diagnostic approach and empiric treatment options. Claveland Clinic Journal of Medicine 2007; 74 (supplement 4): S 21-S 28.
[8]	Cornia PB, Davidson HL, Lipsky BA. The evaluation and treatment of complicated skin and skin structure infections. Expert Opin Pharmacother 2008; 9:717-730.
[9]	Kalaskar A, Venkataramana K. Determination of Antimicrobial Resistance Pattern and Production of Extended-Spectrum β-Lactamases amongst Escherichia coli and Klebsiella pneumoniae from Clinical Isolates. J Med Bacteriol. 2012; 1 (2): pp. 17-24.
[10]	Ramana KV, Mohanty SK, Kumar A. In-vitro activities of current antimicrobial agents against isolates of pyoderma. Indian J Dermatol Venereol Leprol 2008; 74:430.
[11]	Ramana KV, Mohanty SK, Wilson CG. Staphylococcus aureus colonization of anterior nares of school going children. Indian J Pediatr. 2009 Aug; 76(8):813-6.
[12]	Ramana KV and Rao R. Significance of Screening for Colonization and Vancomycin Resistance in Staphylococcus aureus Isolated from Anterior Nares of School Going Children. Online J Health Allied Scs. 2009; 8(3):20.
[13]	Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-1406.
[14]	Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services. Guidance for industry [draft]. Uncomplicated and complicated skin and skin structure infections developing antimicrobial drugs for treatment. July 1998. Available at: http://www.fda.gov/Cder/guidance/2566dft.pdf. Accessed November 6, 2013.
[15]	Papadavid E, Dalamaga M, Stavrianeas N, Papiris SA. Subcutaneous sarcoidosis masquerading as cellulitis. Dermatology 2008; 217:212-214.
[16]	Falagas ME, Vergidis PI. Narrative review: diseases that masquerade as infectious cellulitis. Ann Intern Med 2005; 142:47-55.
[17]	Ellie J. C. Goldstein, Diane M. Citron, C. Vreni Merriam, Yumi Warren, Kerin L. Tyrrell, and Richard M. Gesse. General Microbiology and In Vitro Susceptibility of Anaerobes Isolated from Complicated Skin and Skin-Structure Infections in Patients Enrolled in a Comparative Trial of Ertapenem Versus Piperacillin-Tazobactam. Clin Infect Dis 2002; 35 (suppl 1): S 119-25.
[18]	Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 2007; 27:1506-11.
[19]	Raya-Cruz M, Ferullo I, Arrizabalaga-Asenjo M, Nadal-Nadal A, Díaz-Antolín MP, Garau-Colom M, Payeras-Cifre A. Skin and soft-tissue infections in hospitalized patients: Epidemiology, microbiological, clinical and prognostic factors. Enferm Infecc Microbiol Clin. 2013 May 15. pii: S 0213-005 X (13)00077-3.
[20]	Phakade RS, Nataraj G, Kuyare SS, Khopkar US, Mehta PR. Is methicillin-resistant Staphylococcus aureus involved in community acquired skin and soft tissue infections? Experience from a tertiary care centre in Mumbai. J Postgrad Med. 2012 Jan-Mar; 58(1):3-7.
[21]	Mims C, Playfair J, Roitt I et al. Medical Microbiology. Mosby Int Ltd, London.
[22]	Lala M Dunbar, Derek M Tang and Robert M Manausa. A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI’s). Therapeutics and Clinical Risk Management 2008; 4 (1): 235-244.
[23]	Martin E. Stryjewski, Steven L. Barriere, William O’Riordan, Lala M. Dunbar, Alan Hopkins, Fredric C. Genter and G. Ralph Corey. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections J Antimicob Chemother 2012; 67: 1496-1502.
[24]	Ramana KV, Rao R, Sharada C, Kareem MA, Reddy LR, Ratna Mani MS. Modified Hodge test: A useful and the low cost Phenotypic method for detection of carbapenemase producers in Enterobacteriaceae members. J Nat Sc Biol Med 2013; 4:346-8.
[25]	Brad Spellberg, George H. Talbot, Helen W. Boucher, John S. Bradley, David Gilbert, W Michael Scheld, John Edwards Jr. and John G. Bartlett for the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Antimicrobial Agents for Complicated Skin and Skin-Structure Infections: Justification of Noninferiority Margins in the Absence of Placebo-Controlled Trials Clin Infect Dis 2009; 49 (3): 383-391.
[26]	Keefer CS, Blake FG, Marshall EK Jr, Lockwood JS, Wood BW. Penicillin in the treament of infections. JAMA 1943; 122:1217-24.
[27]	Judith N. Steenbergen, Jeff Alder, Grace M. Thorne and Francis P. Tally. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicob Chemother 2005; 55: 283-288.
[28]	Ronald L Nichols, Donald R Graham, Steven L Barriere, Anthony Rodgers, Samuel E Wilson, Marcus Zervos, David L Dunn and Bruce Kreter for the synercid skin and skin structure infection group. J Antimicob Chemother 1999; 44: 263-273.
[29]	Donald Biek, Ian A. Critchley, Todd A. Riccobene and Dirk A. The Ceftaroline fosamil: a novel broad spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother 2010; 65 Suppl 4: iv9-16.
[30]	Robert C. Moellering Jr. The problem of complicated skin and skin structure infections: the need for new agents. J Antimicrob Chemother 2010; 65 Suppl 4: iv3-8.
[31]	Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61:417-20.
[32]	Dubert M. Guerrero, Federico Perez, Mark D. Adams, Nicholas G. Conger, Philip N. Rather, Joseph S. Solomkin, and Robert A. Bonomo. Acinetobacter baumannii-Associated Skin and Soft Tissue Infections: Recognizing a Broadening Spectrum of Disease. Surg Infect 2011; 11 (1): 49-57.
[33]	Christian Eckmann and Mathew Dryden. Treatment of Complicated skin and soft-tissue infections caused by resistant bacteria: value of linazolid, tigecycline, daptomycin and vancomycin. Eur J Med Res 2010; 15; 554-563.
[34]	Beth White and R Andrew Seaton. Complicated skin and soft tissue infections: Literature review of evidence for and experience with daptomycin. Infection and Drug Resistance 2011; 4: 115-127.
[35]	Yun Cai, Rui Wang, Beibei Liang, Nan Bai and Youning Liu. Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious disease. Antimicrobial agents and Chemotherapy 2011; 55 (3): 1162-1172.
[36]	Inge C. Gyssens, Matthew Dryden, Peter Kujath, Dilip Nathwani, Nicolaas Schaper, Barbara Hampel, Peter Reimnitz, Jeff Alder and Pierre Alvis. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother 2011; 66: 2632-2642.
[37]	Bogner JR, Kutaiman A, Esguerra-Alcalen M, Heldner S, Arvis P. Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study. Adv Ther. 2013 Jun; 30(6):630-43.
[38]	Mircea Radu Mihu and Luis R Martinez. Novel therapies for treatment of multidrug resistant Acinetobacter baumannii skin infections. Virulence 2011; 2 (2): 97-102.
[39]	Shankar R, He LK, Szilagyi A, Muthu K, Gamelli RL, Filutowicz M, et al. A novel antibacterial gene transfer treatment for multidrug resistant Acinetobacter baumannii-induced burn sepsis. J Burn Care Res 2007; 28:6-12.
[40]	Thomas-V irnig CL, Centanni JM, Johnston CE, He LK, Schlosser SJ, Van Winkle KF, et al. Inhibition of multidrug-resistant Acinetobacter baumannii by nonviral expression of hCAP-18 in a bioengineered human skin tissue. Mol Ther 2009; 17:562-9.
[41]	Heilborn JD, Nilsson MF, Kratz G, Weber G, Sørensen O, Borregaard N, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120:37.
[42]	Mowbray M, Tan X, Wheatley PS, Rossi AG, Morris RE, Weller RB. Topically applied nitric oxide induces T-lymphocyte infiltration in human skin, but minimal inflammation. J Invest Dermatol 2008; 128:352-60.
[43]	Soneja A, Drews M, Malinski T. Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmacol Rep 2005; 57:108-19.
[44]	Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A, et al. Sustained release nitric oxide releasing nanoparticles: Characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008; 19:12-20.
[45]	Lin NT, Chiou PY, Chang KC, Chen LK, Lai MJ. Isolation and characterization of phi AB2: a novel bacteriophage of Acinetobacter baumannii. Res Microbiol 2010; 161:308-14.
[46]	Castano AP, Mroz P, Wu MX, Hamblin MR. Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci USA 2008; 105:5495-500.
[47]	Dadachova E, Casadevall A. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. Expert Opin Drug Deliv 2005; 2:1075-84. Radioimmunotherapy.
[48]	Dadachova E, Burns T, Bryan RA, Apostolidis C, Brechbiel MW, Nosanchuk JD, et al. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob Agents Chemother 2004; 48:1624-9.
[49]	Wang HM, Chen Cy, Chen HA, Huang WC, Lin WR, Chen TC, et al. Zingiber officinale (ginger) compounds have tetracycline-resistance modifying effects against clinical extensively drug-resistant Acinetobacter baumannii. Phytother Res 2010; 24:1825-30.
[50]	Tianhong Dai, Asheesh Gupta, Ying-Ying Huang, Margaret E. Sherwood, Clinton K. Murray, Mark S. Vrahas, Tammy Kielian and Michael R. Hamblin Blue Light Eliminates Community-Acquired Methicillin-Resistant Staphylococcus aureus in Infected Mouse Skin Abrasions. Photomedicine and Laser Surjery 2013;31 (11): 531-538.
[51]	Derry K Mercer & Deborah A O’Neil. Peptides as the next generation of anti-infectives. Future Medicinal Chemistry 2013, Vol. 5, No. 3, Pages 315-337.
[52]	Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am. J. Surg. 2003; 85:369-375.
[53]	George H. Talbot, Tanya O’Neal, Anita F. Das, Dirk Thye. Prospective Study of the Wilson Severity-of-Illness Scoring System for Complicated Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy 2013; 57 (1): 647-650.
[54]	Garau, J.; Ostermann, H.; Medina, J.; et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. CLINICAL MICROBIOLOGY AND INFECTION Volume: 19 Issue: 9 Pages: E 377-E 385.
[55]	Eron LJ, Lipsky BA, Low DE et al., Managing skin and soft tissue infections: Expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl 1: i3-17.
[56]	Fernando Albericio and Hendrik G Kruger. Therapeutic Peptides. Future Med Chem 2012; 4 (12): 1527-1531.
[57]	Jenkins TC, Knepper BC, Sabel AL, et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med 2011; 171:1072-1079.
[58]	Hammond SP, Baden LR. Clinical decisions. Management of skin and soft-tissue infection—polling results. N Engl J Med 2008; 359: e 20.